In a regulatory filing, aTyr Pharma (ATYR) disclosed that its director Jane Gross bought 3.8K shares of common stock on March 17th in a total transaction size of $15K. Shares are up 4.5% afterhours at $4.19.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATYR:
- aTyr Pharma (ATYR) Stock Soars 24% on Promising Drug Developments
- Buy Rating Affirmed for aTyr Pharma Amid Strategic Trial Adjustments and Financial Stability
- aTyr Pharma’s Earnings Call Highlights Progress and Challenges
- Strategic Adjustments and Promising Developments Lead to Buy Rating for aTyr Pharma
- aTyr Pharma Reports 2024 Results and Strategic Progress
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue